Both Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Trillium Therapeutics Inc. (NASDAQ:TRIL) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Table 1 highlights Alnylam Pharmaceuticals Inc. and Trillium Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Alnylam Pharmaceuticals Inc. and Trillium Therapeutics Inc.

The average price target of Alnylam Pharmaceuticals Inc. is $124.9, with potential upside of 51.32%. Trillium Therapeutics Inc. on the other hand boasts of a $2.5 average price target and a 342.71% potential upside. Based on the analysts view we can conclude, Trillium Therapeutics Inc. is looking more favorable than Alnylam Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors owned 88% of Alnylam Pharmaceuticals Inc. shares and 39.41% of Trillium Therapeutics Inc. shares. Insiders owned 0.2% of Alnylam Pharmaceuticals Inc. shares. Insiders Competitively, owned 0.37% of Trillium Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Alnylam Pharmaceuticals Inc. had bullish trend while Trillium Therapeutics Inc. had bearish trend.

Summary

Trillium Therapeutics Inc. beats Alnylam Pharmaceuticals Inc. on 6 of the 11 factors.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.